The Top 5 Biosimilars Articles for the Week of February 25

March 1, 2019

The Center for Biosimilars® recaps the top news for the week of February 25, 2019.

Transcript:

Hi, I’m Samantha DiGrande for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.

Here are the top 5 biosimilars articles for the week of February 25.

Number 5: New psoriasis treatment guidelines say that anti—tumor necrosis factor biosimilars can be considered therapeutically interchangeable with their reference products.

Number 4: A newly published paper looks ahead to the potential for—and challenges related to—biosimilars of products like gene and cell therapies.

Number 3: As part of its investigation into drug pricing, the Senate Finance Committee is launching a bipartisan probe into insulin prices.

Number 2: Sandoz has filed suit against Amgen, asking the court for a declaratory judgment of patent noninfringement and invalidity.

Number 1: A judge has directed Boehringer Ingelheim to disclose its launch plans for its biosimilar adalimumab as part of a long-running patent dispute with AbbVie.

Finally, last week, our e-newsletter asked which stakeholder group you think has the most influence in combatting misinformation on biosimlars.

To view results of the poll, visit us on LinkedIn.

To read all of these articles and more, visit centerforbiosimilars.com.